Identifying genetic factors in sporadic chordoma patients
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
National Institutes of Health Clinical Center (CC) · NCT01200680
This study is trying to find out if certain genes, especially the T gene, play a role in causing sporadic chordoma, a rare bone cancer, by looking at the genetic information of patients diagnosed with it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 6 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) (nih) |
| Drugs / interventions | Chemotherapy, radiation |
| Locations | 1 site (Rockville, Maryland) |
| Trial ID | NCT01200680 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify genetic factors that contribute to the susceptibility of sporadic chordoma, a rare bone cancer. It focuses on understanding the role of specific genes, particularly the T gene, in the development of this cancer. By analyzing genetic alterations in patients diagnosed with chordoma, the study seeks to uncover insights into the molecular mechanisms underlying this disease. Participants will include individuals diagnosed with chordoma, regardless of age or tumor location, who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 6 years and older who are the only person in their family diagnosed with chordoma.
Not a fit: Patients with a family history of chordoma or those diagnosed with other types of cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of chordoma and potential new avenues for prevention and treatment.
How similar studies have performed: While there have been studies on familial chordoma, this approach focusing on sporadic cases is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
* ELIGIBILITY CRITERIA: * To be eligible subjects must be at least 6 years old at the time of enrollment, be the only person in their family ever diagnosed with chordoma, and reside in the U.S or Canada. * Chordoma in the patients can have been diagnosed at any age and any primary site.
Where this trial is running
Rockville, Maryland
- Westat, Inc. — Rockville, Maryland, United States (RECRUITING)
Study contacts
- Principal investigator: Alisa M Goldstein, Ph.D. — National Cancer Institute (NCI)
- Study coordinator: NCI Family Study Referrals
- Email: ncifamilystudyreferrals@mail.nih.gov
- Phone: (800) 518-8474
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Genes, Sporadic Chordoma, Pediatric and Adult, Gene Identification, Rare Bone Cancer, All Chordoma Sites, Natural History